Patents by Inventor Scott Thacher

Scott Thacher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrazolopyrimidinone compounds
    Patent number: 12617799
    Abstract: Provided herein are pyrazolopyrimidinone compounds and pharmaceutical compositions comprising said compounds.
    Type: Grant
    Filed: March 25, 2022
    Date of Patent: May 5, 2026
    Assignee: ORPHAGEN PHARMACEUTICALS, INC.
    Inventors: Neil Raheja, Paul Crowe, Haiyan Tao, Scott Thacher
  • PYRAZOLOPYRIMIDINONE COMPOUNDS
    Publication number: 20240208982
    Abstract: Provided herein are pyrazolopyrimidinone compounds and pharmaceutical compositions comprising said compounds.
    Type: Application
    Filed: March 25, 2022
    Publication date: June 27, 2024
    Inventors: Neil RAHEJA, Paul CROWE, Haiyan TAO, Scott THACHER
  • MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA
    Publication number: 20180258133
    Abstract: Methods for modulating (inhibiting or stimulating) retinoid-related orphan receptor ? (ROR?) activity. This modulation has numerous effects, including inhibition of TH-17 cell function and/or TH-17 cell activity, and inhibition of re-stimulation of TH-17 cells, which are beneficial to treatment of inflammation and autoimmune disorders. Stimulation of ROR? results in stimulation of TH-17 cell function and/or activity which is beneficial for immune-enhancing compositions (e.g., vaccines).
    Type: Application
    Filed: May 9, 2018
    Publication date: September 13, 2018
    Inventors: Scott Thacher, Xiaolin Li, Robert Babine, Bruno Tse
  • Modulators of retinoid-related orphan receptor gamma
    Patent number: 9657053
    Abstract: Methods for modulating (inhibiting or stimulating) retinoid-related orphan receptor ? (ROR?) activity. This modulation has numerous effects, including inhibition of TH-17 cell function and/or TH-17 cell activity, and inhibition of re-stimulation of TH-17 cells, which are beneficial to treatment of inflammation and autoimmune disorders. Stimulation of ROR? results in stimulation of TH-17 cell function and/or activity which is beneficial for immune-enhancing compositions (e.g., vaccines).
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: May 23, 2017
    Assignee: ORPHAGEN PHARMACEUTICALS
    Inventors: Scott Thacher, Xiaolin Li, Robert Babine, Bruno Tse
  • Modulators of retinoid-related orphan receptor gamma
    Patent number: 8389739
    Abstract: Methods for modulating (inhibiting or stimulating) retinoid-related orphan receptor ? (ROR?) activity. This modulation has numerous effects, including inhibition of TH-17 cell function and/or TH-17 cell activity, and inhibition of re-stimulation of TH-17 cells, which are beneficial to treatment of inflammation and autoimmune disorders. Stimulation of ROR? results in stimulation of TH-17 cell function and/or activity which is beneficial for immune-enhancing compositions (e.g., vaccines).
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: March 5, 2013
    Assignee: Orphagen Pharmaceuticals
    Inventors: Scott Thacher, Xiaolin Li, Robert Babine, Bruno Tse
  • Methods of treating hyperlipidemia
    Publication number: 20050171151
    Abstract: The current invention relates to methods for treating hyperlipidemia in mammals, including humans. More specifically, the current invention relates to the use of retinoid or retinoid derivative that is able to act as an antagonist or inverse agonist of a retinoid receptor to treat hyperlipidemia.
    Type: Application
    Filed: December 17, 2004
    Publication date: August 4, 2005
    Applicant: Allergan, Inc.
    Inventors: Yang-Dar Yuan, Scott Thacher, Elliott Klein, Roshantha Chandraratna
  • Methods of screening for compounds that modulate hormone receptor activity
    Publication number: 20050130232
    Abstract: The present invention provides methods for identifying an effective agent that modulates a biological activity of a nuclear hormone receptor. In a method of the invention, an isolated receptor-containing complex is assayed for an altered modification state as compared to a control modification state. The presence of an altered modification state serves to identify an effective agent that modulates a biological activity of the nuclear hormone receptor.
    Type: Application
    Filed: August 20, 2004
    Publication date: June 16, 2005
    Applicant: Allergan, Inc.
    Inventors: Yi Zhao, Scott Thacher, Jia-Hao Xiao, Jyotirmoy Kusari, Roshantha Chandraratna
  • Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A
    Publication number: 20040077721
    Abstract: vitamin A, or a derivative of vitamin A having vitamin A like activity is co-administered with inhibitors of the CP450RAI1 and/or of CP450RAI2 enzymes for the purpose of treating diseases and conditions in mammals, including humans, which diseases or conditions are prevented, treated, ameliorated, or the onset of which is delayed by administration of retinoid compounds or by the mammalian organism's naturally occurring retinoic acid.
    Type: Application
    Filed: September 5, 2003
    Publication date: April 22, 2004
    Inventors: Yang-Dar Yuan, Jayasree Vasudevan, Scott Thacher, Roshantha A. Chandraratna